References
- Sawzdargo M, Nguyen T, Lee DK et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 64(2), 193–198 (1999).
- Ryberg E, Larsson N, SjɆgren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092–1101 (2007).
- Johns DG, Behm DJ, Walker DJ et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152(5), 825–831 (2007).
- Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362(4), 928–934 (2007).
- Piñeiro R, Falasca M. Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim. Biophys. Acta 1821(4), 694–705 (2012).
- Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T. 2-arachidonoyl-snglycero- 3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 145(1), 13–20 (2009).
- Siehler S. Regulation of RhoGEF proteins by G12/13-coupled receptors. Br. J. Pharmacol. 158(1), 41–49 (2009).
- Godlewski G, Offertȥler L, Wagner JA, Kunos G. Receptors for acylethanolamides – GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 89(3–4), 105–111 (2009).
- Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 27(7), 762–778 (2006).
- Moreno-Navarrete JM, Catalȥn V, Whyte L et al. The L-a-lysophosphatidylinositol/ GPR55 system and its potential role in human obesity. Diabetes 61(2), 281–291 (2012).
- Ho WS. Angiogenesis: a new physiological role for N-arachidonoyl serine and GPR55? Br. J. Pharmacol. 160(7), 1580–1582 (2010).
- Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat. Rev. Drug Discov. 9(2), 107–115 (2010).
- Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90(3), 1138–1144 (1992).
- Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, Bernardini R. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol. 82(4), 380–388 (2012).
- Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochim. Biophys. Acta 1822(1), 14–20 (2012).
- Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries. Biochem. Biophys. Res. Commun. 227(2), 479–483 (1996).
- Jenkin KA, McAinch AJ, Grinfeld E, Hryciw DH. Role for cannabinoid receptors in human proximal tubular hypertrophy. Cell Physiol. Biochem. 26(6), 879–886 (2010).
- PiɁeiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30(2), 142–152 (2012).
- Lin XH, Yuece B, Li YY et al. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol. Motil. 23(9), 862–e342 (2012).